

# PHARMACEUTICAL INDUSTRY IN KEY FIGURES

+80

production units

+40

pharmaceutical laboratories

+40

companies with foreign participation

+13500

direct jobs

+1400 MTND investments in the drug market

+3400

locally manufactured medicines

+200 MTND

in exports


#### **SUCCESS STORIES**

ADWYA, ADHE, CAIR TUNISIE, CONSOMED, DAR ESSAYDALI, FM. BIZERTE, GALPHARMA, HIKMA, IPS, MACOMED, MEDIS, OPALIA, PHARMAGHREB, SAIPH, SANOFI, SIMED, SIPHAT, TERIAK, UNIMED.

## A STRATEGIC AND PRIORITY SECTOR

- · All pharmaceutical forms are manufactured in Tunisia
- 3 out of 4 locally consumed medicines are manufactured in Tunisia
- The sector exports to 35 countries in the world including 24 African countries
- Exports have tripled in 5 years. They currently represent 18% of production.

## HIGH LEVEL HUMAN CAPITAL




Source: fDi Benchmark, the Financial Times Ltd, 2021

#### **Competitive wages**

- Guaranteed Minimum Inter-professional Wage (SMIG) 365.732 TND ≈ 113.742 € (40 hour schedule)
- Guaranteed Minimum Agricultural Wage (SMAG): 16.512 TND ≈ 5.135 € (daily wage)

## **COMPETITIVE PRODUCTION COSTS**



Source: fDi Benchmark, the Financial Times Ltd. 2021

## ATTRACTIVE LEGISLATIVE AND REGULATORY FRAMWORKS

- Tax exemption for profits from investments for five to ten years in regional development zones
- A range of incentives to boost investment in the pharmaceutical and biotechnology industries
- Coverage of employer contributions and infrastructure expenses in regional development zones
- · Possibility for the foreign investor to own up to 100% of the capital of implemented projects
- Investment grants to support regional development of up to 30%
- Premium for the development of employment capacity
- Preferential tax and customs regime for the acquisition of equipment
- · Simplified customs declaration procedures.

### **CONDUCIVE ECOSYSTEMS**

- Dedicated research and development centres: the biotechnology technopole of Sidi Thabet, the Pasteur Institute of Tunis, the Biotechnology Centre of Sfax
- · A pharmaceutical pact to improve the national ecosystem in terms of infrastructure, governance, training and investment
- Draft charter of public-private partnership in the pharmaceutical industries by 2025 to increase the competitiveness of the sector's stakeholders
- A National Quality Assurance System for Medicines that meets international standards.

#### **INVESTMENT OPPORTUNITIES**

• Generic medicines • Vaccines and biotechnology-based medicines • Flavours • Paramedical products • Packaging items • Pharmaceutical glassware • Biotechnology • Outsourcing of research and development activities.



#### **TUNISIA RANKED AS THE:**

2nd

- health system in Africa in 2021 Source: World Population Review
- world destination for thalassotherapy after France Source: The National Office of Thermalism and Hydrotherapy
- in the field of health tourism in Africa Source: North Africa Health, IM







www.investintunisia.tn

Cologne London Madrid Milan Paris

fipa.cologne@investintunisia.de fipa.london@investintunisia.org.uk fipa.madrid@investintunisia.es fipa.milan@investintunisia.it fipa.paris@investintunsia-org.fr